期刊文献+

左旋多巴对偏侧帕金森病大鼠纹状体多巴胺D_2受体表达数及多巴胺含量的影响 被引量:1

Effects of L-dopa on cells expressing D_2 receptors and level of dopamine transmitter in hemiparkinsonian rats
下载PDF
导出
摘要 目的了解左旋多巴(L-dopa)在抗帕金森病(PD)治疗中对纹状体区多巴胺D2受体表达数及多巴胺含量的影响。方法采用6-羟基多巴胺(6-OHDA)制备偏侧PD大鼠模型。用免疫组化染色法和高效液相色谱法分别检测PD模型大鼠在L-dopa100mg·kg-1·d-1)腹腔注射15d前后纹状体部位的多巴胺D2受体表达数、多巴胺及其代谢物含量变化。结果与L-dopa治疗前组相比,L-dopa治疗后PD大鼠模型纹状体中D2受体阳性表达细胞数明显减少(P<0.01),而多巴胺和代谢物含量明显增高。结论偏侧PD大鼠模型损毁侧纹状体区多巴胺D2受体因代偿作用出现明显上调,而L-dopa干预能很大程度逆转了这种上调作用。 OBJECTIVE To investigate the effects of L-dopa on cells expressing D2 receptors and level of dopamine transmitter in striatum in the treatment of Parkinson' s disease ( PD). METHODS Hemiparkinsonian model was established on rats pretreated with 6-hydroxydopamine, The cells of expression of D2 receptor and the level of dopamine transmitters in striatum were detected respectively by immunohistochemical staining and HPLC before and after introducing L-dopa ( 100 mg·kg^-1·d^-1, ip) to PD model for 15 d. RESULTS Compared with before-treatment group, decreased significantly whereas the level of dopamine transmitter at the lesioned side striatum increased significantly after L-dopa intervention to PD model, the cells expressing D2 receptor at the lesioned side striatum( P 〈 0.01 ). CONCLUSION The cells expressing of D2 receptor are compensatively upregulated at the lesioned side striatum in hemiparkinsonian rats. However, this upregulative effect can be reversed by L-dopa intervention to a great extent.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2005年第15期1149-1151,共3页 Chinese Pharmaceutical Journal
基金 浙江省卫生厅资助项目(10015)
关键词 帕金森病 左旋多巴 D2受体 神经递质 Parkinson' s disease L-dopa D2 receptor neurotransmitter
  • 相关文献

参考文献11

  • 1周嘉伟,武义鸣,徐慧君,冯家笙.帕金森病大白鼠动物模型的建立[J].南通医学院学报,1989,9(2):84-86. 被引量:13
  • 2Leenders KL, Slamon EP, Tyrell P, et al.The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease[ J].Arch Neurol, 1990, 47(12): 1290.
  • 3Murata M. The therapy of wearing-off[ J ]. Nippon Rinsho, 2004, 62(9): 1716.
  • 4Thomas J, Wang J, Takuba H, et al. A 6-OHDA induced selective Parkinsonian rat model: further biochemical and behavioural characterization [ J ]. Exp Neurol , 1994,126:159.
  • 5Perese DA,Ulman J, Viola J, etal. 6-OHDA induced selective parkinsonion[J]. Brain Res ,1989,494(2):285.
  • 6Sokoloff P, Schwartz JG. Novel dopamine receptors half a decade later[ J]. Trends Pharmacol Sci, 1995,16: 270.
  • 7Qin ZH, Chen JF, Weiss B. Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the disensity, rate of synthesis,and level of gene expession of D1 and D2 dopamine receptors [ J ]. J Neurochem ,1994 , 62 : 411.
  • 8Shinotoh H, Hirayama K, Tateno Y. Dopamine D1 and Dopamine D2 receptors in Pakinson's disease and strianigral degeneration determined by PET [ J ]. Adv Neurol , 1993,60: 488.
  • 9Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-dopa following repeated administration in the 6-hydroxydopamine lesioned rat model of Parkinson's disease[J]. Exp Neurol, 1998,151(2) :334.
  • 10Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism[ J]. Ann Neurol, 1980,8:558.

共引文献12

同被引文献10

  • 1陈执中.表面等离子共振技术在新药开发研究中的应用进展[J].药物生物技术,2004,11(5):336-338. 被引量:5
  • 2Mathley R W,Nathan B P,Pitas R E.Apolipoprotein E is structure,function and possible roles in Alzheimer's disease[J].Ann N YAcad Sci,1996,777:139-145.
  • 3Silkose D T.Alzheimer's disease:genotype phentypes and treatments[J].Science,1997,275(5300):630-631.
  • 4Bohrmann B,Tjemberg L,Kuner P,et al.Endogenous proteins controlling amyloid β-peptide polymerization[J].J Boil Chem,1999,274(23):15990-15995.
  • 5Cohen E,Bieschke J,Perciavalte M,et al.Opposing activities protect against age-onset proteotoxicity[J].Science,2006,313:1604-1610.
  • 6Leenders K L,Slamon E P,Tyrell P,et al.The nigrostriatal dopaminergic system assessed in vitro by position emission tomography in healthy volunteer subjuects and patients with Parkinson's disease[J].Arch Neurol,1990,47(12):1290-1294.
  • 7Sokoloff P,Schwartz J G.Novel dopamine receptors half a decade later[J].Trends Pharnacol Sci,1995,16:270-273.
  • 8Cooper A A,Gitler A D,Cashikar A,et al.α-Synuclein blocks ER-Golgi traffic and Rabl I resues neuron loss in Parkinson models[J].Science,2006,313:324-328.
  • 9Neumann M,Smpathu D M,Kwong L K,et al.Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis[J].Science,2006,314:130-133.
  • 10陈执中.老年痴呆症防治新药研究进展[J].中国药学杂志,1997,32(5):260-263. 被引量:28

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部